291 related articles for article (PubMed ID: 26501907)
1. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
Bauer SM; Kubiak JM; Rothbauer U; Laufer S
Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
[TBL] [Abstract][Full Text] [Related]
2. A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition data.
Anton R; Bauer SM; Keck PR; Laufer S; Rothbauer U
PLoS One; 2014; 9(4):e95641. PubMed ID: 24743242
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors.
Williams RG; Kandasamy R; Nickischer D; Trask OJ; Laethem C; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():364-89. PubMed ID: 17110203
[TBL] [Abstract][Full Text] [Related]
4. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
Yego EC; Dillman JF
Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
[TBL] [Abstract][Full Text] [Related]
5. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform.
Trask OJ; Baker A; Williams RG; Nickischer D; Kandasamy R; Laethem C; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():419-39. PubMed ID: 17110205
[TBL] [Abstract][Full Text] [Related]
6. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
[TBL] [Abstract][Full Text] [Related]
7. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
Hendriks BS; Seidl KM; Chabot JR
BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
[TBL] [Abstract][Full Text] [Related]
8. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen.
Almholt DL; Loechel F; Nielsen SJ; Krog-Jensen C; Terry R; Bjørn SP; Pedersen HC; Praestegaard M; Møller S; Heide M; Pagliaro L; Mason AJ; Butcher S; Dahl SW
Assay Drug Dev Technol; 2004 Feb; 2(1):7-20. PubMed ID: 15090206
[TBL] [Abstract][Full Text] [Related]
9. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.
Wilson BA; Alam MS; Guszczynski T; Jakob M; Shenoy SR; Mitchell CA; Goncharova EI; Evans JR; Wipf P; Liu G; Ashwell JD; O'Keefe BR
J Biomol Screen; 2016 Mar; 21(3):277-89. PubMed ID: 26538432
[TBL] [Abstract][Full Text] [Related]
11. Endoplasmic reticulum-associated ubiquitin-conjugating enzyme Ube2j1 is a novel substrate of MK2 (MAPKAP kinase-2) involved in MK2-mediated TNFα production.
Menon MB; Tiedje C; Lafera J; Ronkina N; Konen T; Kotlyarov A; Gaestel M
Biochem J; 2013 Dec; 456(2):163-72. PubMed ID: 24020373
[TBL] [Abstract][Full Text] [Related]
12. Regulation of monocyte subset proinflammatory responses within the lung microvasculature by the p38 MAPK/MK2 pathway.
O'Dea KP; Dokpesi JO; Tatham KC; Wilson MR; Takata M
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L812-21. PubMed ID: 21873449
[TBL] [Abstract][Full Text] [Related]
13. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells.
Chen TH; Kao YC; Chen BC; Chen CH; Chan P; Lee HM
Eur J Pharmacol; 2006 Jul; 541(3):138-46. PubMed ID: 16765938
[TBL] [Abstract][Full Text] [Related]
14. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement.
Soegaard-Madsen L; Johansen C; Iversen L; Kragballe K
Br J Dermatol; 2010 Jun; 162(6):1216-23. PubMed ID: 20346019
[TBL] [Abstract][Full Text] [Related]
16. Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases.
Kjellerup RB; Kragballe K; Iversen L; Johansen C
Exp Dermatol; 2008 Jun; 17(6):498-504. PubMed ID: 18081851
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.
Alimbetov D; Davis T; Brook AJ; Cox LS; Faragher RG; Nurgozhin T; Zhumadilov Z; Kipling D
Biogerontology; 2016 Apr; 17(2):305-15. PubMed ID: 26400758
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
Singh RK; Diwan M; Dastidar SG; Najmi AK
Hum Exp Toxicol; 2018 May; 37(5):521-531. PubMed ID: 28629242
[TBL] [Abstract][Full Text] [Related]
20. Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species.
Fehr S; Unger A; Schaeffeler E; Herrmann S; Laufer S; Schwab M; Albrecht W
Cell Physiol Biochem; 2015; 36(6):2237-49. PubMed ID: 26279429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
